We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Way to Identify Influenza A Virus Could Pave Way for More Sensitive Tests

By LabMedica International staff writers
Posted on 08 Jun 2022

The influenza A virus, which is responsible for seasonal flu outbreaks, causes between 290,000 and 650,000 deaths per year globally. More...

Because the influenza A virus is constantly changing, or mutating, it can be difficult to detect, treat, and inoculate against. To solve this problem, researchers are looking for parts of the influenza virus that do not change when the virus mutates. A panhandle structure on the virus known as the promoter region or promoter has emerged as a potential target. By finding new ways to target specific parts of the influenza A virus that do not change when the virus mutates, this research could be used to create more sensitive tests that can detect the influenza A virus more easily.

In order to quickly detect the presence of the influenza A virus, researchers at Tohoku University (Sendai, Japan) have developed a fluorogenic probe that could bind to the promoter region of the influenza A virus RNA. A fluorogenic probe is based on small molecules called fluorophores that emit light when a specific target is present. In the new study, the fluorogenic probe researchers created binds to part of the promoter region that consists of double-strand RNA structure carrying the internal loop, creating a significant light-up response that can identify the presence of influenza A. In order to create the fluorogenic probe, researchers used a type of synthetic DNA called peptide nucleic acid (PNA). The triplex-forming PNA can be specifically developed to target the double-stranded RNA in the panhandle structure of the influenza A virus RNA in the sequence-selective manner. Researchers then combined the triplex forming PNA having a type of dye called thiazole orange with a small molecule that would bind with the internal loop structure of the RNA.

This combination is called a conjugate. To determine how effective the conjugate was, researchers first analyzed how brightly the conjugate glowed when it was bound to the target panhandle structure of the promoter region. It was more than 130-fold brighter than when it was not bound to anything. Compared to the small molecules alone, the combination of the PNA and the small molecules had a stronger binding affinity by two orders of magnitude. This result shows how promising this technique could be for the diagnosis of influenza A, since the promoter region remains stable no matter the strain of influenza. In the future, this could even be a promising target for antiviral drugs that could treat infections of influenza A.

"The promoter region of influenza A virus RNA has emerged as a new target for biochemical and therapeutic application because the sequences are not involved in the gene variations related to pathogenesis (how the flu virus develops) and antiviral resistance," said Yusuke Sato, an associate professor at Tohoku University. "These results represent the development of new molecular probes for influenza A research, with a view toward the diagnosis of influenza A infection, as well as the design of new antivirus drugs targeting the influenza A virus RNA promoter region."

"The research group demonstrated the selective fluorescence response of the conjugate for total RNA from influenza A virus H1N1-infected cells over that from mock-infected ones," added Sato. "This technique would serve as a promising candidate for the analysis of influenza A virus RNA based on the direct sensing of the influenza A virus RNA promoter region, in sharp contrast to the gold standard PCR method."

Related Links:
Tohoku University 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.